High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion.

Nilius, Verena; Killer, Madeleine C; Timmesfeld, Nina; Schmitt, Melina; Moll, Roland; Lorch, Anja; Beyer, Jörg; Mack, Elisabeth; Lohoff, Michael; Burchert, Andreas; Neubauer, Andreas; Brendel, Cornelia (2018). High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. Oncoimmunology, 7(5), e1423169. Taylor & Francis 10.1080/2162402X.2017.1423169

[img]
Preview
Text
2018 OncoImmunology Brendel.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (930kB) | Preview

Survival of patients with germ-cell cancer (GCC) and primary progression or relapse after cisplatin-based first-line chemotherapy is highly heterogeneous, ranging from close to zero to more than 70%. We investigated β-1,4-Galactosyltransferase-I () expression levels in peripheral lymphocytes in a cohort of 46 testicular cancer patients. enhances immune cell crosstalk via glycosylation of surface molecules. A high expression level of in T-lymphocytes, but not in monocytes, was associated with a lower risk of relapse with a hazard ratio (HR) of 0.66 (95% confidence interval (CI) of HR: 0.45-0.97; = 0.02) upon multivariate Cox regression analysis. Correspondingly, interleukin 10 (IL10), a cytokine released by cytotoxic T-cells, was likewise significantly elevated in T-lymphocytes of non-relapse GCC patients (HR: 0.3; 95% CI of HR: 0.14-0.65; = 0.002). Our data indicate that glycosylation and activation of T-lymphocytes may play a pivotal role in disease control in GCC patients with primary progressive or relapsed disease.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Beyer, Jörg

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2162-4011

Publisher:

Taylor & Francis

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

19 Mar 2019 13:53

Last Modified:

22 Oct 2019 21:28

Publisher DOI:

10.1080/2162402X.2017.1423169

PubMed ID:

29721375

Uncontrolled Keywords:

B4GALT1 T-lymphocytes biomarker germ-cell cancer immunosurveillance

BORIS DOI:

10.7892/boris.124935

URI:

https://boris.unibe.ch/id/eprint/124935

Actions (login required)

Edit item Edit item
Provide Feedback